Trials / Completed
CompletedNCT01970397
JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines
A Prospective, Randomized, Controlled, Multi-center Study of the Safety and Effectiveness of JUVEDERM® Ultra XC Injectable Gel Versus Belotero Balance® for Perioral Lines
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, randomized, controlled, multi-center study of the safety and effectiveness of JUVEDERM® Ultra XC injectable gel versus Belotero Balance® for perioral lines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | JUVEDERM® Ultra XC | Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment). |
| DEVICE | Belotero Balance® | Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment). |
Timeline
- Start date
- 2013-10-21
- Primary completion
- 2014-08-04
- Completion
- 2014-08-04
- First posted
- 2013-10-28
- Last updated
- 2019-04-16
- Results posted
- 2015-09-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01970397. Inclusion in this directory is not an endorsement.